AlivaMab Discovery Services is Expanding the Drug Discovery Platform with the Introduction of New Antibody Engineering Department

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expertise in antibody engineering includes bispecific antibodies, some of which have reached clinical trials, antibody-drug conjugates, Fc modification, in vitro display for antibody discovery and optimization, and structural modeling.

“An increasing number of leading pharma and biotechs realize that ADS's pre-existing platform process adds exceptional value to their antibody drug discovery efforts. I am excited to be leading the initiative at ADS to develop new capabilities that will expand the scope and importance that we offer to our clients' drug discovery and development projects. The new Antibody Engineering Department's commitment will help to ensure that ADS delivers the best antibody drug candidates,” said Jonah Rainey, Vice President of Antibody Engineering at AlivaMab Discovery Services.

“Today, we significantly expand the ADS discovery platform by adding a new pillar of antibody engineering to our existing pillars of Ablexis' AlivaMab® Mouse, the leading transgenic animal technology for antibody drug discovery, a suite of AMMPD immunization technologies to address even the most challenging targets, a broad sampling of the immune repertoire through function-first high-throughput deep sequencing, and a broad sampling of the immune repertoire through function-first high-throughput sequence analysis. “Jonah's skills and abilities complement and reinforce the ADS team's accumulated decades of experience in discovery and development. We assist our clients in delivering quality medicines to patients quicker by combining team, technology, and partnership.”

About AlivaMab Discovery Services
AlivaMab Discovery Services is a privately-owned biotechnology company that develops an integrated antibody therapeutic discovery platform that combines innovative technologies and deep expertise to produce superior antibody therapeutics on time. Throughout their careers, the team has completed over 200 discovery projects, yielding several antibody drug candidates in clinical trials. ADS offers a wide range of antibody therapeutic candidates with complex molecular and epitope profiles, functional and kinetic characterization, and superior developability profiles.ADS is trusted by organizations ranging from global pharmaceutical firms to virtual biotechnology companies because of its business model that relies solely on partners instead of developing an internal product pipeline.



Related News